A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 304
- Registration Number
- NCT01283516
- Locations
- 🇺🇸
University of Colorado School of Medicine Colorado Univ, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering MSK, New York, New York, United States
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
- Conditions
- Systolic Hypertension
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 910
- Registration Number
- NCT01281306
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
- Conditions
- Acute Lymphoblastic LeukemiaChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT01279473
- Locations
- 🇯🇵
Novartis Investigative Site, Aichi, Japan
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
- Conditions
- Histologically-proven and Radiologically-confirmed Solid Tumors
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT01278849
- Locations
- 🇳🇿
Novarts Investigative Site, Auckland, New Zealand
🇳🇿Novartis Investigative Site, Wellington, New Zealand
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
- Conditions
- Metastatic Cancer
- Interventions
- Drug: ASA404, DMXAA or DXAA
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT01278758
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Hematology/Oncology Dept., Indianapolis, Indiana, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Joseph Ford Cancer Center/Clinical Trials Office, Henry Ford Health System, Detroit, Michigan, United States
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT01278342
- Locations
- 🇮🇹
Novarts Investigative Site, Naples, Italy
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Conditions
- Transplantation Infection
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT01276457
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT01275209
- Locations
- 🇺🇸
Sarah Cannon Research Institute SC - 2, Chattanooga, Tennessee, United States
🇺🇸Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT01275222
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
🇺🇸Dana Farber Cancer Institute Dept of Sarcoma Oncology, Boston, Massachusetts, United States
🇺🇸College of Physicians and Surgeons of Columbia University, New York, New York, United States
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 267
- Registration Number
- NCT01275196
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China